agilon health Reports Deepening Losses, Major Asset Impairments, and NYSE Delisting Threat; Amends Credit Facility Amid Lawsuits

summarizeSummary

The 10-K filing reveals a company under significant financial and operational pressure. The substantial increase in net loss and Adjusted EBITDA loss, coupled with a negative medical margin, indicates a deteriorating core business performance. The ongoing threat of NYSE delisting, necessitating a reverse stock split, highlights severe marketability and investor confidence issues. The significant impairment charges on goodwill and intangible assets further underscore a re-evaluation of asset values and future prospects. While the credit agreement amendment provides short-term debt maturity relief, the tightened covenants and reduced revolving credit capacity suggest increased financial scrutiny and limited flexibility. The multiple pending lawsuits add to the company's legal and reputational risks. Investors should be aware of the severe challenges facing the company, including its ability to achieve profitability, maintain its listing, and navigate complex legal and regulatory environments.

check_boxKey Events

• Significant Financial Deterioration in 2025

  The company reported a net loss of $391.3 million for fiscal year 2025, a significant increase from $260.1 million in 2024. Adjusted EBITDA loss also widened to $296.2 million from $154.2 million, and medical margin turned negative at $(56.6) million compared to a positive $205.2 million in 2024. Cash used in operating activities increased to $105.8 million from $57.8 million.

• NYSE Delisting Threat and Reverse Stock Split Plan

  agilon health received a notice on November 5, 2025, from the NYSE for non-compliance with the $1.00 average closing price rule. The company is pursuing a reverse stock split, with a proposed ratio of one-for-five to one-for-twenty-five, subject to stockholder approval at a special meeting on March 17, 2026, to regain compliance.

• Substantial Asset Impairments Recorded

  The company recognized $36.1 million in non-cash impairment charges in 2025, including a $24.1 million goodwill impairment (reducing its carrying value to zero) and a $12.0 million impairment related to trade names.

• Credit Agreement Amended with Stricter Terms

  On February 10, 2026, the company amended its credit agreement, extending the maturity date to February 18, 2028. However, the amendment also reduced revolving credit commitments from $100.0 million to $90.0 million, required a minimum daily cash balance of $50.0 million, and conditioned certain payments on achieving positive EBITDA for two consecutive trailing four-quarter periods.

auto_awesomeAnalysis

The 10-K filing reveals a company under significant financial and operational pressure. The substantial increase in net loss and Adjusted EBITDA loss, coupled with a negative medical margin, indicates a deteriorating core business performance. The ongoing threat of NYSE delisting, necessitating a reverse stock split, highlights severe marketability and investor confidence issues. The significant impairment charges on goodwill and intangible assets further underscore a re-evaluation of asset values and future prospects. While the credit agreement amendment provides short-term debt maturity relief, the tightened covenants and reduced revolving credit capacity suggest increased financial scrutiny and limited flexibility. The multiple pending lawsuits add to the company's legal and reputational risks. Investors should be aware of the severe challenges facing the company, including its ability to achieve profitability, maintain its listing, and navigate complex legal and regulatory environments.